Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies KT-621 parallel Phase 2b